Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
A recent study also found that having a higher body mass index was associated with a higher risk of fatty liver disease.
Twelve states have an adult obesity prevalence of 35% or more.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.
A recent study found one in five people with HIV should be assessed for fatty liver, and 1 in 10 should be referred to a liver specialist.
Gastrointestinal cancers conference emphasizes patient quality of life.
Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.